For the last 10 years, data have been accumulating indicating that, contrary to former evidence, lithium may play a useful role in the treatment of certain schizophrenic patients. Delva & Letemendia (1982) , after reviewing major controlled and uncontrolled studies in this area, concluded that â€oe¿ between one third and one-half of patients with schizophrenia will benefit from lithiumâ€•.
In two of the controlled studies, lithium alone was shown to be better than placebo (Alexander et a!, (1979) , who included schizoaffective patients in their controlled study, found that the subgroup of â€˜¿ schizophrenicschizo affective' (36Â°/a of their patients) showed considerably less total improvement than the subgroup of affective schizoaffective patients. However, the beneficial effect of lithium carbonate added to haloperidol was at least as apparent in this group as in the affective subgroup. Regarding symptom specificity, Growe Other studies (Small et a!, 1975; Biederman et a!, 1979; Delva et a!, 1981; Braden eta!, 1982; Zemlan eta!, 1984) found lithium also had a beneficial effect on symptoms of thought disorder in schizophrenic patients.
Reanalysing the Brief Psychiatric Rating Scale (BPRS) data of Biederman et al's (1979) study by using non-parametric statistical techniques for multi dimensional evaluation of ratings, Shalif eta! (1981) showed that the beneficial effect of the lithium supplementation was most apparent in those schizo phrenic patients who were on the depressive side of the median (as rated by the anxietyâ€"depressive items of the BPRS). That group responded poorly to neuroleptics alone. In order to demonstrate that respondents to lithium supplementation did not in fact represent the affective pole of the schizoaffective patients (as detected by the BPRS items), we decided to replicate the design of our former study (Biederman et a!, 1979), but to include this time only true schizophrenic, or clearly schizophrenic schizoaffective patients.
Method
All psychotic patients admitted to Eitanim Psychiatric Hospital, Jerusalem, who met the RDC criteria for schizophrenicand schizoaffectivedisorder -mainlyschizo phrenic (Spitzer et a!, 1978) were referred to the study. Patients outside the age range 18â€"55, or suffering from any cardiovascular systemic or organomental disease, were excluded. All patients had given informed consent. Patients who received, during the 2 weeks prior to admission, neuroleptics for more than 2 days, or a depot injection of neuroleptics, were excluded. The study was of a double blind design. Haloperidol treatment was begun on the day of admission and continued until the end of the study, with dosages prescribed by the ward psychiatrist as required by the clinical status of the patients. Anti-Parkinson treatment (trihexyphenidyl) was given routinely. After 2 weeks, each patient began receiving an additional four capsules of lithium carbonate (300mg per day), or identical capsules of placebo. Patients were assigned to treatment by lithium or placebo in a random order. The study continued for 8 weeks. Serum lithium levels were monitored by the control psychiatrist (YL). Placebo patients' blood samples were assigned dummy results.
Response to the study treatment was assessed by using the BPRS. All patients were assessed independently by the two ward psychiatrists (YL and MS) who were unaware of the lithiumâ€"placebo schedule. Scores were assigned by consensus between the two raters. Every patient was rated on admission to the study project, and then on weeks 2, 4, 6, and 8.
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Lithium Combined with Haloperidol in Schizophrenic Patients
YAACOV LERNER,YAACOV MINTZER and MIGUEL SCHESTATZKY
Previously, the addition of lithium to haloperidol has been reported to be of modest benefit to schizoaffective patients. To test this treatment on a different sample, 36 mainly schizophrenic patients were subdivided on the basis of the median of their initial depression score on the BPRSinto depressive and non-depressive schizophrenic subjects. Each group randomly received haloperidol plus placebo or haloperidol plus lithium for 8 weeks. The schizophrenic patients who were on thedepressive sideofthemedian BPRS depression score were found to be the most resistant to neuroleptic treatment alone, and benefited from the addition of lithium. 
Results
Of the 41 patients who enteredthe study, fivewereexcluded due to lack of co-operation in taking drug treatment. Of these, three patients were dropped after 3 weeks, and two after 4 weeks. They included two in the lithium group and three in the placebo group. The characteristics of the five patients in the drop-out group did not differ from those in the study group (Table I) . The remaining 36 patients were divided into two subgroups according to the median of their initial depressiveâ€"anxietycore on the BPRS. The relevant items to this score are: somatic concern, anxiety, guilt feelings, and depression (Guy eta!, 1976) . Eighteen patients scored less than 4 on the depression factor (â€˜non-depressed schizophrenics'), and 18scored 4 or more (â€˜depressed schizo phrenics'). This terminology will be used on the basis of their relative depression score, even if dinically their depression was mild. Of the 18 depressed patients, nine received the haloperidol and lithium treatment and nine received halo peridol and placebo. The same was true of the 18 non depressed patients (Table I) The two grouping factors were â€˜¿ treatment' (lithium or placebo) and â€˜¿ state of patients' (depressed vs non-depressed). The dependent variable, BPRS, was measured repeatedly five different times on weeks 0,2,4,6, and 8. No interaction between the repeated measure variable, time, and treatment (lithiumâ€"no lithium) was found. Also, no interaction between the repeated measures and the state of the patient 44. The placebo-depressed group (anxietyâ€"depression @4) scoreswere significantly higher (Scheffee test statistic = 10.9, P< 0.05).
(depressiveâ€"non-depressive) was found. When the two grouping factors were combined in the analysis (creating four different groups), the interaction between the repeated Analysis of variance with repeated measures was used for these items but only two time points were tested â€"¿ baseline and week eight. Interaction between â€˜¿ treatment' (lithium vs. placebo) and â€˜¿ state of patient' (depressed vs. non depressed) turned out to be significant (F=4.4l; d.f. = 1, 32; P <0.05). This means that when combined treatment (lithium plus haloperidol) was given to depressed schizo phrenic patients, their scores on thought disorder decreased more than those of non-depressed schizophrenic patients receiving haloperidol plus placebo. Since haloperidol was not prescribed in this study on a fixed-dosage schedule, but on the basis of the clinical decision of the ward psychiatrist, a separate analysis was done to study possible differences in the dosages given to the four groups of patients. It was found that from week 6, the average prescribed dosage of haloperidol was gradually reduced in the two lithium groups. As shown in Table II , the average haloperidol dosage for the lithium-depressed group showed the sharpest reduction (26.1 mg/day for week 8) as compared with all other groups, especially as compared with the placebo-depressed group. In the latter group, no decrease of average daily dosage of haloperidol was found (43.3 mg/day in week 8, and an average of 47.6 mg/day for all 8 weeks).
Discussion
Although it was conducted with schizophrenic and not schizoaffective patients, this study confirms the findings of our earlier one (Biederman et a!, 1979; Shalif et a!, 1981 ) that the addition of lithium to haloperidol has a beneficial effect mainly for those schizophrenic subjects who have some depressive symptoms from the beginning of their psychotic state. This is in contrast to Carman et al's (1981) findings, that the effect of lithium is mainly on the arousal component of the schizophrenic symptoms; yet half of Carman et al's patients were schizoaffective and most of their respondents came from that subgroup.
Our patients were mainly schizophrenic (according to the RDC criteria). When we applied the DSMâ€"III (American Psychiatric Association, 1980) criteria for schizophrenia, 28 of the patients still met the criteria for schizophrenia (15 from the non-depressive group, 13 from the depressive group). The depressive items of the BPRS, although of possible predictive value regarding drug treatment, were not severe enough in our patients to give a clinical diagnosis of schizoaffective dis order. The Hamilton Rating Scale for Depression (Hamilton, 1967) was not used, because of the claim that it was based on a clinical population of major depressed patients and is not suitable for measuring depressive symptoms in schizophrenic patients.
The fact that depressive symptoms are part of true schizophrenia is well documented (Planansky & of haloperidol were prescribed by the ward psychiatrist who was blind to the design and hypotheses of the study. The finding that the depressed patients who received placebo required clinically higher dosages of haloperidol compared with the depressed patients who received lithium is a validation of the higher BPRS scores attributed to the placebo-depressed group compared with the lithium-depressed group.
It can be concluded that the depressive schizo phrenic group, otherwise resistant to haloperidol, benefited most from the addition of lithium, while the non-depressive schizophrenic patients improved their BPRS measurements whether or not lithium was added to haloperidol (Fig. 1) 
